Plans to Dose First Human Subjects in Phase 1 in Q2 2021 Vancouver, British Columbia (Newsfile Corp. - March 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"),
NervGen Pharma Corp.: NervGen Pharma Adds Alzheimer s Disease Patient Cohort to Its Phase 1 Clinical Trial Program
cdavis@lifesciadvisors.com
Follow NervGen on Twitter (@NervgenC) and LinkedIn (NervGen Pharma Corp.) for the latest news on the Company.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities legislation. Such forward-looking statements and information herein include, but are not limited to, the Company s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements
NervGen Pharma Corp.: NervGen Pharma Establishes Alzheimer s Disease Scientific Advisory Board
Vancouver, British Columbia (Newsfile Corp. - January 26, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer s Disease Scientific Advisory Board ( AD-SAB ) with the appointment of four world-class scientists and clinical researchers in Alzheimer s disease: Jeffrey Cummings, MD, ScD; George Perry, PhD; Henrik Zetterberg, MD, PhD; and Bruce Lamb, PhD. The AD-SAB will work closely with NervGen as the Company plans its upcoming preclinical studies and clinical trials and in the analyses of the results from these studies.